Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
André J. Scheen. (2013) Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors: From Risk Factors to Clinical Outcomes. Postgraduate Medicine 125:3, pages 7-20.
Read now
Read now
Bo Ahrén. (2013) Incretin therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors. European Diabetes Nursing 10:1, pages 31-36.
Read now
Read now
Articles from other publishers (28)
Dandan Xie, Yutong Li, Murong Xu, Xiaotong Zhao & Mingwei Chen. (2022) Effects of dulaglutide on endothelial progenitor cells and arterial elasticity in patients with type 2 diabetes mellitus. Cardiovascular Diabetology 21:1.
Crossref
Crossref
Ji-Bing He, Xin-Yi Ma, Wen-Jie Li, Ying-Ying Liu & Ding-Sheng Lin. (2021) Exenatide inhibits necrosis by enhancing angiogenesis and ameliorating ischemia/reperfusion injury in a random skin flap rat model. International Immunopharmacology 90, pages 107192.
Crossref
Crossref
Giulia Cantini, Martina Trabucco, Ilaria Dicembrini, Edoardo Mannucci & Michaela Luconi. 2020. Hormonal Signaling in Biology and Medicine. Hormonal Signaling in Biology and Medicine
361
381
.
I. Dicembrini, M. Monami & E. Mannucci. (2019) Dypeptidylpeptidase-4 inhibitors and the cardiovascular system: How to manage the fil rouge. Nutrition, Metabolism and Cardiovascular Diseases 29:3, pages 215-219.
Crossref
Crossref
Junling Liu, Kun Yang, Jin Yang, Wenhua Xiao, Yunyi Le, Fei Yu, Liangbiao Gu, Shan Lang, Qing Tian, Tianru Jin, Rui Wei & Tianpei Hong. (2019) Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output. EBioMedicine 41, pages 73-84.
Crossref
Crossref
Matteo Monami, Stefania Zannoni, Laura Pala, Antonio Silverii, Francesco Andreozzi, Giorgio Sesti & Edoardo Mannucci. (2017) Effects of glucagon-like peptide-1 receptor agonists on mortality and cardiovascular events: A comprehensive meta-analysis of randomized controlled trials. International Journal of Cardiology 240, pages 414-421.
Crossref
Crossref
Giulia Cantini, Edoardo Mannucci & Michaela Luconi. (2016) Perspectives in GLP-1 Research: New Targets, New Receptors. Trends in Endocrinology & Metabolism 27:6, pages 427-438.
Crossref
Crossref
Stefano Bacci, Annunziatina Laurino, Maria Elena Manni, Elisa Landucci, Claudia Musilli, Gaetano De Siena, Alessandra Mocali & Laura Raimondi. (2015) The pro-healing effect of exendin-4 on wounds produced by abrasion in normoglycemic mice. European Journal of Pharmacology 764, pages 346-352.
Crossref
Crossref
Barbara Sottero, Simona Gargiulo, Isabella Russo, Cristina Barale, Giuseppe Poli & Franco Cavalot. (2015) Postprandial Dysmetabolism and Oxidative Stress in Type 2 Diabetes: Pathogenetic Mechanisms and Therapeutic Strategies. Medicinal Research Reviews 35:5, pages 968-1031.
Crossref
Crossref
M. Buysschaert, D. Amoussou-Guenou, D. Yanogo & F. Djrolo. (2015) Impact cardiovasculaire des incrétino-mimétiques chez le diabétique de type 2 : le point en 2015. Médecine des Maladies Métaboliques 9:2, pages 158-163.
Crossref
Crossref
Liang Wang, Ye Liu, Jin Yang, Hejun Zhao, Jing Ke, Qing Tian, Lin Zhang, Jinhua Wen, Rui Wei & Tianpei Hong. (2014) GLP-1 Analog Liraglutide Enhances Proinsulin Processing in Pancreatic β-Cells via a PKA-Dependent Pathway. Endocrinology 155:10, pages 3817-3828.
Crossref
Crossref
Gerhard H. Scholz & Holger Fleischmann. (2014) Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making. Therapeutic Advances in Endocrinology and Metabolism 5:5, pages 95-123.
Crossref
Crossref
U. M. Mogensen, C. Andersson, E. L. Fosbøl, T. K. Schramm, A. Vaag, N. M. Scheller, C. Torp-Pedersen, G. Gislason & L. Køber. (2014) Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus - a retrospective nationwide study. Diabetes, Obesity and Metabolism 16:10, pages 1001-1008.
Crossref
Crossref
Guillermo E. Umpierrez & Stanley Schwartz. (2014) Use Of Incretin-Based Therapy in Hospitalized Patients with Hyperglycemia. Endocrine Practice 20:9, pages 933-944.
Crossref
Crossref
Hejun Zhao, Rui Wei, Liang Wang, Qing Tian, Ming Tao, Jing Ke, Ye Liu, Wenfang Hou, Lin Zhang, Jin Yang & Tianpei Hong. (2014) Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner. American Journal of Physiology-Endocrinology and Metabolism 306:12, pages E1431-E1441.
Crossref
Crossref
Matteo Monami, Ilaria Dicembrini, Camilla Nardini, Irene Fiordelli & Edoardo Mannucci. (2014) Glucagon-like peptide-1 receptor agonists and pancreatitis: A meta-analysis of randomized clinical trials. Diabetes Research and Clinical Practice 103:2, pages 269-275.
Crossref
Crossref
M. Krempf. (2014) Étude de la saxagliptine sur la survenue d’événements cardiovasculaires chez des patients diabétiques de type 2 (Étude SAVOR-TIMI 53) : les résultats. Médecine des Maladies Métaboliques 8:1, pages 61-64.
Crossref
Crossref
Ilaria Dicembrini, Michela Bigiarini & Edoardo Mannucci. (2014) Lixisenatide: clinical profile and available evidence. Diabetes Management 4:1, pages 71-84.
Crossref
Crossref
Alex Blatt, Eli Shiloah, Sa’ar Mincha, Olga Bloch & Micha J. Rapoport. (2013) Incretin hormone glucagon-like peptide-1 is increased in patients with acute-phase ST-elevation myocardial infarction treated with a primary percutaneous coronary intervention. Cardiovascular Endocrinology 2:4, pages 98-102.
Crossref
Crossref
Jaime A. Davidson. (2013) Incretin-Based Therapies: Focus on Effects Beyond Glycemic Control Alone. Diabetes Therapy 4:2, pages 221-238.
Crossref
Crossref
Yao Dai, Dongsheng Dai, Federico Mercanti, Zufeng Ding, Xianwei Wang & Jawahar L. Mehta. (2013) Dipeptidyl peptidase-4 inhibitors in cardioprotection: a promising therapeutic approach. Acta Diabetologica 50:6, pages 827-835.
Crossref
Crossref
Matthias Tacke, Nicole Ebner, Michael Boschmann, Annett Jarius, Miroslava Valentova, Susann Fülster, Anja Sandek, Lutz Schomburg, Stefan D. Anker, Wolfram Doehner & Stephan von Haehling. (2013) Resting Energy Expenditure and the Effects of Muscle Wasting in Patients With Chronic Heart Failure: Results From the Studies Investigating Comorbidities Aggravating Heart Failure (SICA-HF). Journal of the American Medical Directors Association 14:11, pages 837-841.
Crossref
Crossref
M. Monami, S. Genovese & E. Mannucci. (2013) Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes, Obesity and Metabolism 15:10, pages 938-953.
Crossref
Crossref
Edoardo Mannucci, Ilaria Dicembrini, Angelo Lauria & Paolo Pozzilli. (2013) Is Glucose Control Important for Prevention of Cardiovascular Disease in Diabetes?. Diabetes Care 36:Supplement_2, pages S259-S263.
Crossref
Crossref
Carlo Maria Rotella, Laura Pala & Edoardo Mannucci. (2013) Role of Insulin in the Type 2 Diabetes Therapy: Past, Present and Future. International Journal of Endocrinology and Metabolism 11:3.
Crossref
Crossref
André J. Scheen. (2013) Cardiovascular effects of gliptins. Nature Reviews Cardiology 10:2, pages 73-84.
Crossref
Crossref
L. Pala & C. M. Rotella. (2013) The Role of DPP4 Activity in Cardiovascular Districts: In Vivo and In Vitro Evidence. Journal of Diabetes Research 2013, pages 1-5.
Crossref
Crossref
Chrysi Koliaki & John Doupis. (2012) Linagliptin/Metformin Fixed-Dose Combination Treatment: A Dual Attack to Type 2 Diabetes Pathophysiology. Advances in Therapy 29:12, pages 993-1004.
Crossref
Crossref